Surgical Oncology News

This section features a sampling of news related to surgical oncology from the popular press, from press releases received, or SSO news directly pertinent to SSO members.

SSO Reveals Selection of Top Cancer Symposium Abstracts for SSO 2015

Author: SSO Staff
Date:
Apr 07, 2015

ROSEMONT, Ill. —The Society of Surgical Oncology (SSO) is proud to reveal the abstracts from the top research presentations slated for the 68th SSO Annual Cancer Symposium. The Symposium (SSO 2015) takes place March 25-28 at the George R. Brown Convention Center in Houston, Texas, where the leading minds in surgical oncology will come together to explore the future of the treatment, diagnosis and management of cancer.

“These abstracts are representative of the most noteworthy research being done today,” said SSO President Ronald J. Weigel, MD, PhD, Professor and Chairman, Department of Surgery, University of Iowa Carver College of Medicine. “SSO 2015 offers an excellent opportunity for cancer professionals to explore some of the most important findings of the year and immerse themselves in the discussions and debates surrounding them.”

This year’s top abstracts include:

Targeted Axillary Dissection Improves Axillary Evaluation following Neoadjuvant Chemotherapy in Node Positive Patients—University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Friday, March 27, 8:31 a.m.

This study was designed to determine whether pathologic changes in clipped nodes reflect nodal responses to neoadjuvant chemotherapy (NCT) and if targeted axillary dissection (TAD) improves the accuracy of nodal assessment. Of the 129 node-positive patients enrolled, 40.3 percent had a complete nodal response to NCT and 59.7 percent had residual disease. Pathologic evaluation of the clipped node revealed metastases in 73 of 77 patients with residual disease, resulting in a false negative rate (FNR) for the clipped node of 5.2 percent. In 71 patients who underwent sentinel lymph node dissection (SNLD), 60.6 percent of patients had residual nodal disease. The clipped node revealed disease in four of these five cases, thus evaluation of the clipped node in addition to the SLN(s) improved the false negative rate to 2.3 percent.

- more -
 
The Impact of Health Insurance on Cancer Care in Disadvantaged Communities—University of Michigan, Ann Arbor, Michigan, United States
Friday, March 27, 8:43 a.m.

This study examined whether health insurance can mitigate the effects of social determinants on health in disadvantaged communities. In the study, the Surveillance, Epidemiology, and End Results (SEER) registries were linked to U.S. census data for patients diagnosed with the four leading causes of cancer deaths from 2007-2011. A county-level composite measure was constructed based on median  household income, proportion of residents below the poverty level and proportion of married couples. For all cancer types, patients from the most disadvantaged communities were found to be more likely to present with distant disease and had higher cancer-specific mortality than the least disadvantaged communities.

An Externally Validated Prognostic Multigene Expression Assay for Survival in Resected Colorectal Liver Metastases—Memorial Sloan Kettering Cancer Center, New York, New York, United States and University Medical Center, Heidelberglaan, Utrecht, Netherlands
Friday, March 27, 8:57 a.m.

Detailing the first molecular risk score (MRS) to externally validate multigene assay to prognosticate outcomes in resected colorectal liver metastases (CRLM). This study looked to develop and externally validate a prognostic multigene expression assay after the resection of CRLM. Two sites were chosen: the Memorial Sloan Kettering Cancer Center (MSKCC) and the University Medical Center (UMC) Utrecht. For overall survival (OS) at MSKCC, the molecular risk score (MRS) was found to be the strongest independent prognosticator. MRS was also prognostic of background recurrence free (RFS). For OS at UMC Utrecht, MRS was the only independent prognosticator. MRS was also prognostic of RFS. The clinical risk scores were not independently prognostic of OS in either dataset and only the Fong score was prognostic of RFS in the UMC Utrecht study.

Proteomic Features of Colorectal Cancer Predict Relapse-free Survival and Identify Tumor Subgroups Independent of Oncogenic Mutations—MD Anderson Cancer Center, Houston, Texas, United States
Friday, March 27, 9:21 a.m.

This trial used reverse-phase protein arrays (RPPA) to analyze the prognostic implications of the functional proteome in stage 2/3 CRC and aimed to identify patterns of protein expression that drive tumorigenesis. Twelve proteins were revealed to be significant predictors of tumor recurrence on univariate analysis including key players in the energy balance/MTOR signaling pathway: AMPK, mTOR, PI3Kp85 and FoxO3a. On multivariate analysis, phospho-Bad, FoxO3a, HER3 and phospho-S6 remained significant. Clustering revealed dichotomization with Group 1, notable for high EMT (fibronectin, collagen VI, low E-cad), with Group 2 found to be high in Akt/MTOR pathway components (BRAF, HER2/3).

- more -
 
To see all abstracts for all of the presentations to be held at SSO 2015, visit 
SSO2015.org. Members of the media are invited to attend the presentations at SSO 2015 and report upon the findings after the date of the presentation. The abstracts specific to this press release are embargoed until Friday, March 27 at 10am CDT. All other abstracts presented at SSO 2015 are embargoed until after their specific presentation in Houston. For a copy of the complete SSO 2015 Media Guidelines, visit SSO2015.org. To receive a media registration, please contact Anne O’Day at aoday@davidjamesgroup.com. Be sure to keep up with the latest SSO 2015 news on Twitter using #SSO2015.

###

About the Society of Surgical Oncology
Founded in 1940 as the James Ewing Society, the Society of Surgical Oncology® is the premier organization for surgeons and health care providers dedicated to advancing and promoting the science and treatment of cancer worldwide. The 2,800-member Society's focus on all solid-tumor disease sites is reflected in its Annual Cancer Symposium, monthly scientific journal (Annals of Surgical Oncology), educational initiatives and committee structure.

Download the PDF